Cosmo Pharmaceuticals reports remarkable business achievements

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) reported full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.95 per share at the next AGM on 27 May 2022.

Business Highlights:

  • FDA approved GI Genius™, the first-to-market device that uses artificial intelligence (AI) to assist clinicians in the detection of lesions in the colon in real time during a colonoscopy.
  • DETECT study showed AI assistance using GI Genius™ reduces missed polyp rate by over 50% on initial colonoscopy.
  • Signed licence and supply agreement between Cassiopea S.p.A. and Sun Pharmaceutical Industries for Winlevi® in the U.S. and Canada.
  • Winlevi® launched by Sun Pharmaceutical Industries in the U.S. in November 2021.
  • Cosmo launched and successfully closed public exchange offer to acquire Cassiopea S.p.A.

Japan income fundJPMorgan Japan Small Cap Growth & Income (LONJSGI), targets Japan income without compromising on Japanese growth opportunities. This Japan income investing opportunity gives investors access to a diverse and fast growing sector managed by local managers. The Investment Trust offers a regular quarterly income without compromising on Japanese growth opportunities, by paying a higher dividend funded part by capital reserves as well as revenue returns.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
JPMorgan Japan Small Cap Growth & Income

More articles like this

JPMorgan Japan Small Cap Growth & Income

Japan economy grows 0.4% in Q4, avoids recession

Japan’s economy expanded at an annualized clip of 0.4% in October to December from the previous quarter, better than the initial estimate for a 0.4% contraction, government data showed on Monday. The revised figure for gross

JPMorgan Japan Small Cap Growth & Income

Japan ISA investing for tax-free growth and income

Investing in Japan is the hot investment topic with Japan’s equity market Nikkei stock average topping the 40,000 mark for the first time on 4 March 2024. DirectorsTalk caught up with Alexa Henderson, Non-executive chairman of JPMorgan

JPMorgan Japan Small Cap Growth & Income

Japan’s Nikkei hits second consecutive record high

Japan’s Nikkei share average scaled record highs for the second consecutive session, supported by upbeat performances in pharmaceuticals, although profit-taking capped some of those gains. The Nikkei ended 0.35% higher at a new closing high of 39,233.71.